Inclusion body myositis associated with human T-lymphotropic virus-type I infection: Eleven patients from an endemic area in Japan

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 1, 2008, Pages 41-49

  Matsuura, Eiji ^a   Umehara, Fujio ^a   Nose, Hirohisa ^a   Higuchi, Itsuro ^a   Matsuoka, Eiji ^a   Izumi, Koutarou ^a   Kubota, Ryuji ^a   Saito, Mineki ^b   Izumo, Shuji ^a   Arimura, Kimiyoshi ^a   Osame, Mitsuhiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytotoxic T cell; HAM TSP; HTLV I; Inclusion body myositis; Pentamer

Indexed keywords

HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PREDNISOLONE; TAU PROTEIN; TAX PROTEIN; VIRUS DNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG DOSE TITRATION; ENDEMIC DISEASE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; JAPAN; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; MUSCLE BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPASTIC PARESIS; SPINAL CORD DISEASE; VIRUS INFECTION; VIRUS LOAD;

AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE PRODUCTS, TAX; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IN SITU HYBRIDIZATION; JAPAN; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; RETROSPECTIVE STUDIES; SILVER STAINING;

EID: 37549060637     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e31815f38b7     Document Type: Article

References (48)

1. Mikol J, Felten-Papaiconomou A, Ferchal F, et al. Inclusion-body myositis: Clinicopathological studies and isolation of an adenovirus type 2 from muscle biopsy specimen. Ann Neurol 1982;11:576-81
2. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-72
3. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 2000;55:1385-87
4. Dalakas MC. Sporadic inclusion body myositis - Diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-47
5. Sekul EA, Dalakas MC. Inclusion body myositis: New concepts. Semin Neurol 1993;13:256-63
6. Engel WK, Askanas V. Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects. Neurology 2006;66:S20-29
7. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-93
8. Dalakas MC, Rakocevic G, Shatunov A, Goldfarb L, Raju R, Salajegheh M. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol 2007;61:466-75
9. Honma S, Yamada K, Moriwaka F, Shima K, Tashiro K. A case of HTLV-1 associated myelopathy and adult T-cell leukemia, presenting unique muscle pathology including rimmed vacuole. Rinsho Shinkeigaku 1991;31:1129-34
10. Ozden S, Gessain A, Gout O, Mikol J. Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 2001;32:510-14
11. Littleton ET, Man WD, Holton JL, et al. Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure. J Neurol Neurosurg Psychiatry 2002;72:650-52
12. Warabi Y, Matsubara S, Mizutani T, Hayashi H. Inclusion body myositis after interferon-alpha treatment in a patient with HCV and HTLV-1 infection. Rinsho Shinkeigaku 2004;44:609-14
13. Ozden S, Cochet M, Mikol J, Teixeira A, Gessain A, Pique C. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 2004;78:10320-27
14. de The G, Gessain A. Seroepidemiologic data on viral infections (HTLV-I and LAV/HTLV-III) in the Caribbean region and intertropical Africa. Ann Pathol 1986;6:261-64
15. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-32
16. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-10
17. Umehara F, Izumo S, Nakagawa M, et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993;52:424-30
18. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990;348:245-48
19. Bieganowska K, Hollsberg P, Buckle GJ, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol 1999;162:1765-71
20. Umehara F, Nakamura A, Izumo S, et al. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: A possible mechanism to control viral infection in the central nervous system. J Neuropathol Exp Neurol 1994;53:617-24
21. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997;15:15-37
22. Tajima K, Tominaga S, Suchi T, Fukui H, Komoda H, Hinuma Y. HTLV-I carriers among migrants from an ATL-endemic area to ATL non-endemic metropolitan areas in Japan. Int J Cancer 1986;37:383-87
23. Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996;55:774-86
24. Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT. Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues. J Immunol 2000;165:613-17
25. Matsuoka E, Takenouchi N, Hashimoto K, et al. Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis: Double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Acta Neuropathol (Berl) 1998;96:340-46
26. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995;1:1274-78
27. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 1999;96:3848-53
28. Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000;165:7278-84
29. Furukawa Y, Yamashita M, Usuku K, Izumo S, Nakagawa M, Osame M. Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2000;182:1343-49
30. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4:586-93
31. Ando Y, Nakano S, Saito K, et al. Transmission of adult T-cell leukemia retrovirus (HTLV-I) from mother to child: Comparison of bottle- with breast-fed babies. Jpn J Cancer Res 1987;78:322-24
32. Higuchi I, Montemayor ES, Izumo S, Inose M, Osame M. Immunohistochemical characteristics of polymyositis in patients with HTLV-I-associated myelopathy and HTLV-I carriers. Muscle Nerve 1993;16:472-76
33. Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 1997;120:653-61
34. Bangham CR, Hall SE, Jeffery KJ, et al. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci 1999;354:691-700
35. Inose M, Higuchi I, Yoshimine K, et al. Pathological changes in skeletal muscle in HTLV-I-associated myelopathy. J Neurol Sci 1992;110:73-78
36. Higuchi I, Hashimoto K, Kashio N, et al. Detection of HTLV-I provirus by in situ polymerase chain reaction in mononuclear inflammatory cells in skeletal muscle of viral carriers with polymyositis. Muscle Nerve 1995;18:854-58
37. Higuchi I, Hashimoto K, Matsuoka E, et al. The main HTLV-I-harboring cells in the muscles of viral carriers with polymyositis are not macrophages but CD4+ lymphocytes. Acta Neuropathol (Berl) 1996;92:358-61
38. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion - body myositis. Neurology 2006;66:S33-38
39. Nogalska A, Wojcik S, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 2007;204:610-18
40. Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004;164:1-7
41. Sawada M, Suzumura A, Kondo N, Marunouchi T. Induction of cytokines in glial cells by trans activator of human T-cell lymphotropic virus type I. FEBS Lett 1992;313:47-50
42. Alefantis T, Mostoller K, Jain P, Harhaj E, Grant C, Wigdahl B. Secretion of the human T cell leukemia virus type I transactivator protein tax. J Biol Chem 2005;280:17353-62
43. Ozden S, Mouly V, Prevost MC, Gessain A, Butler-Browne G, Ceccaldi PE. Muscle wasting induced by HTLV-1 tax-1 protein: An in vitro and in vivo study. Am J Pathol 2005;167:1609-19
44. Saito M, Higuchi I, Saito A, et al. Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 2002;186:1231-41
45. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994;15:269-74
46. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol 1992;141:31-36
47. Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993;34:551-60
48. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824-35